Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) shares, rose in value on Friday, March 28, with the stock price up by 0.24% to the previous day’s close as strong demand from buyers drove the stock to $637.36.
Actively observing the price movement in the last trading, the stock closed the session at $635.83, falling within a range of $631.45 and $642.97. The value of beta (5-year monthly) was 0.268 whereas the PE ratio was 16.65 over 12-month period. Referring to stock’s 52-week performance, its high was $1211.20, and the low was $629.02. On the whole, REGN has fluctuated by -9.31% over the past month.
With the market capitalization of Regeneron Pharmaceuticals, Inc currently standing at about $69.68 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-03. The company’s Forward Dividend Ratio is 0.88, with its dividend yield at 0.14%.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 14.59B, with a low estimate of 3.12B and a high estimate of 3.72B. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 3.4B.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that REGN’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 2.73, with the price of REGN currently trading nearly -5.57% and -6.86% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 37.48, while the 7-day volatility ratio is showing 2.57% which for the 30-day chart, stands at 3.09%. Furthermore, Regeneron Pharmaceuticals, Inc (REGN)’s beta value is 0.43, and its average true range (ATR) is 19.64.
A comparison of Regeneron Pharmaceuticals, Inc (REGN) with its peers suggests the former has fared considerably weaker in the market. REGN showed an intraday change of 0.24% in last session, and over the past year, it shrunk by -33.85%%.
Data on historical trading for Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) indicates that the trading volumes over the past 10 days have averaged 0.94 and over the past 3 months, they’ve averaged 928.52K. According to company’s latest data on outstanding shares, there are 107.80 million shares outstanding.
Nearly 3.59% of Regeneron Pharmaceuticals, Inc’s shares belong to company insiders and institutional investors own 86.36% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.25 million shares as on 2025-03-14, resulting in a short ratio of 3.59. According to the data, the short interest in Regeneron Pharmaceuticals, Inc (REGN) stood at 314.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 2.2 million. The stock has fallen by -10.52% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the REGN stock heading into the next quarter.
